151 related articles for article (PubMed ID: 28802661)
1. Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience.
van Veenendaal LM; Madu MF; Tesselaar MET; Verhoef C; Grünhagen DJ; van Akkooi ACJ
Eur J Surg Oncol; 2017 Nov; 43(11):2157-2162. PubMed ID: 28802661
[TBL] [Abstract][Full Text] [Related]
2. Merkel cell carcinoma: an unusual indication for isolated limb perfusion.
Ponte P; Moniz JV; Farricha V; Weinholtz JB
Dermatol Online J; 2008 Jul; 14(7):6. PubMed ID: 18718190
[TBL] [Abstract][Full Text] [Related]
3. Long-term response of isolated limb perfusion with hyperthermia and chemotherapy for Merkel cell carcinoma.
Duprat JP; Domingues AL; Coelho EG; Leal RM; Nishinari K; Neves RI
Eur J Surg Oncol; 2009 Jun; 35(6):568-72. PubMed ID: 19013049
[TBL] [Abstract][Full Text] [Related]
4. Isolated limb perfusion with tumor necrosis factor and melphalan for limb salvage in 186 patients with locally advanced soft tissue extremity sarcomas. The cumulative multicenter European experience.
Eggermont AM; Schraffordt Koops H; Klausner JM; Kroon BB; Schlag PM; Liénard D; van Geel AN; Hoekstra HJ; Meller I; Nieweg OE; Kettelhack C; Ben-Ari G; Pector JC; Lejeune FJ
Ann Surg; 1996 Dec; 224(6):756-64; discussion 764-5. PubMed ID: 8968230
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic isolated limb perfusion with tumor necrosis factor alpha, interferon gamma, and melphalan for locally advanced nonmelanoma skin tumors of the extremities: a multicenter study.
Olieman AF; Liénard D; Eggermont AM; Kroon BB; Lejeune FJ; Hoekstra HJ; Koops HS
Arch Surg; 1999 Mar; 134(3):303-7. PubMed ID: 10088573
[TBL] [Abstract][Full Text] [Related]
6. Factors affecting survival after complete response to isolated limb perfusion in patients with in-transit melanoma.
Zogakis TG; Bartlett DL; Libutti SK; Liewehr DJ; Steinberg SM; Fraker DL; Alexander HR
Ann Surg Oncol; 2001 Dec; 8(10):771-8. PubMed ID: 11776490
[TBL] [Abstract][Full Text] [Related]
7. Isolated limb perfusion in Merkel cell carcinoma offers high rate of complete response and durable local-regional control: Systematic review and institutional experience.
Thiels CA; Gonzalez AB; Gray RJ; Jakub JW
J Surg Oncol; 2016 Aug; 114(2):187-92. PubMed ID: 27189050
[TBL] [Abstract][Full Text] [Related]
8. Isolated limb perfusion for unresectable melanoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel BN; Eggermont AM; Kroon BB
Arch Surg; 2004 Nov; 139(11):1237-42. PubMed ID: 15545572
[TBL] [Abstract][Full Text] [Related]
9. Repeat isolated limb perfusion with TNFalpha and melphalan for recurrent limb melanoma after failure of previous perfusion.
Noorda EM; Vrouenraets BC; Nieweg OE; van Geel AN; Eggermont AM; Kroon BB
Eur J Surg Oncol; 2006 Apr; 32(3):318-24. PubMed ID: 16412605
[TBL] [Abstract][Full Text] [Related]
10. Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients.
Madu MF; Deken MM; van der Hage JA; Jóźwiak K; Wouters MWJM; van Akkooi ACJ
Ann Surg Oncol; 2017 Jul; 24(7):1997-2005. PubMed ID: 28188500
[TBL] [Abstract][Full Text] [Related]
11. Repeat isolated limb perfusion with melphalan for recurrent melanoma of the limbs.
Klop WM; Vrouenraets BC; van Geel BN; Eggermont AM; Klaase JM; Nieweg OE; Kroon BB
J Am Coll Surg; 1996 Jun; 182(6):467-72. PubMed ID: 8646345
[TBL] [Abstract][Full Text] [Related]
12. Isolated limb perfusion with tumour necrosis factor-alpha and melphalan with or without interferon-gamma for the treatment of in-transit melanoma metastases: a multicentre randomized phase II study.
Liénard D; Eggermont AM; Koops HS; Kroon B; Towse G; Hiemstra S; Schmitz P; Clarke J; Steinmann G; Rosenkaimer F; Lejeune FJ
Melanoma Res; 1999 Oct; 9(5):491-502. PubMed ID: 10596916
[TBL] [Abstract][Full Text] [Related]
13. Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- alpha versus toxicity after melphalan alone.
Vrouenraets BC; Eggermont AM; Hart AA; Klaase JM; van Geel AN; Nieweg OE; Kroon BB
Eur J Surg Oncol; 2001 Jun; 27(4):390-5. PubMed ID: 11417986
[TBL] [Abstract][Full Text] [Related]
14. Isolated limb perfusion with tumor necrosis factor-alpha and melphalan for patients with unresectable soft tissue sarcoma of the extremities.
Noorda EM; Vrouenraets BC; Nieweg OE; van Coevorden F; van Slooten GW; Kroon BB
Cancer; 2003 Oct; 98(7):1483-90. PubMed ID: 14508836
[TBL] [Abstract][Full Text] [Related]
15. Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.
Olofsson R; Mattsson J; Lindnér P
Int J Hyperthermia; 2013 Sep; 29(6):551-7. PubMed ID: 23865737
[TBL] [Abstract][Full Text] [Related]
16. Tumour response after hyperthermic isolated limb perfusion for locally advanced melanoma.
Paulsen IF; Chakera AH; Drejøe JB; Klyver H; Dahlstrøm K; Oturai PS; Mortensen J; Hesse B; Schmidt G; Drzewiecki K
Dan Med J; 2014 Jan; 61(1):A4741. PubMed ID: 24393586
[TBL] [Abstract][Full Text] [Related]
17. Palliative isolated limb perfusion for advanced limb disease in stage IV melanoma patients.
Takkenberg RB; Vrouenraets BC; van Geel AN; Nieweg OE; Noorda EM; Eggermont AM; Kroon BB
J Surg Oncol; 2005 Aug; 91(2):107-11. PubMed ID: 16028280
[TBL] [Abstract][Full Text] [Related]
18. Isolated limb perfusion as a treatment option for rare types of tumours.
Belgrano V; Ben-Shabat I; Bergh P; Olofsson Bagge R
Int J Hyperthermia; 2016 Sep; 32(6):595-9. PubMed ID: 27269515
[TBL] [Abstract][Full Text] [Related]
19. In-transit Merkel cell carcinoma treated with isolated limb perfusion or isolated limb infusion: a case series of 12 patients.
Zeitouni NC; Giordano CN; Kane JM
Dermatol Surg; 2011 Mar; 37(3):357-64. PubMed ID: 21324044
[TBL] [Abstract][Full Text] [Related]
20. Repeated isolated limb perfusion in melanoma patients with recurrent in-transit metastases.
Deroose JP; Grünhagen DJ; Eggermont AM; Verhoef C
Melanoma Res; 2015 Oct; 25(5):427-31. PubMed ID: 26110555
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
